• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Ascendis Pharma A/S

    8/13/25 12:49:42 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Ascendis Pharma AS

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    04351P101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04351P101


    1Names of Reporting Persons

    Capital International Investors
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,099,512.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,109,225.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,109,225.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ascendis Pharma AS
    (b)Address of issuer's principal executive offices:

    TUBORG BOULEVARD 12, HELLERUP, Denmark
    Item 2. 
    (a)Name of person filing:

    Capital International Investors
    (b)Address or principal business office or, if none, residence:

    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c)Citizenship:

    N/A
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    04351P101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,109,225 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 3,109,225 shares or 5.6% of the 55,754,437 shares believed to be outstanding. Shares reported include 3,109,225 Depository Receipts, which represent 3,109,225 Common Stock.
    (b)Percent of class:

    5.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,099,512

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    3,109,225

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Capital International Investors
     
    Signature:Jae Won Chung
    Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
    Date:08/12/2025
    Get the next $ASND alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    7/3/2025$250.00Overweight
    Morgan Stanley
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    1/7/2025$196.00Buy
    UBS
    9/5/2024$180.00Perform → Outperform
    Oppenheimer
    6/25/2024$156.00 → $175.00Hold → Buy
    TD Cowen
    5/31/2024$200.00Buy
    Stifel
    12/20/2023$150.00Buy
    Jefferies
    More analyst ratings

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Ascendis Pharma with a new price target

    Morgan Stanley resumed coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $250.00

    7/3/25 7:49:10 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Ascendis Pharma from Equal-Weight to Overweight and set a new price target of $250.00

    5/5/25 8:26:14 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ascendis Pharma with a new price target

    RBC Capital Mkts initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $205.00

    4/16/25 9:07:14 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    SEC Filings

    View All

    SEC Form 144 filed by Ascendis Pharma A/S

    144 - Ascendis Pharma A/S (0001612042) (Subject)

    8/15/25 4:15:10 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S

    SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    8/14/25 10:57:53 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    8/13/25 4:01:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ascendis Pharma Reports Second Quarter 2025 Financial Results

    – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions  – Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning –Conference call today at 4:30 pm ET COPENH

    8/7/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

    COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascen

    7/31/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

    First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease companyOn track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA*, as well as combination therapy trials in achondroplasia and hypochondroplasia, in Q4 2025 COPENHAGEN, Denmark, July 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone

    7/28/25 7:00:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma Reports Second Quarter 2025 Financial Results

    – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions  – Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning –Conference call today at 4:30 pm ET COPENH

    8/7/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

    COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascen

    7/31/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

    - For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well to

    6/9/25 7:00:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 1:28:32 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Leadership Updates

    Live Leadership Updates

    View All

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

    COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

    1/29/24 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care